The invention relates to antibodies and antigen binding fragments thereof that are capable of binding to influenza B virus hemagglutinin (HA) and neutralizing influenza B virus in two phylogenetically distinct lineages. In one embodiment, the antibody or antigen binding fragment is capable of binding to influenza B virus hemagglutinin and neutralizing influenza B virus in Yamagata and Victoria lineages.

The present disclosure provides an antibody capable of binding to an intranuclear protein of an influenza virus and an application thereof. The present disclosure provides an antibody capable of recognizing a peptide consisting of the 205th-231st amino acid sequence in SEQ ID NO: 24.

The invention relates to antibodies and binding fragments thereof that are capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus. In one embodiment, an antibody or binding fragment according to the invention is capable of binding to and/or neutralizing one or more influenza A virus group 1 subtypes selected from H1, H2, H5, H6, H8, H9, H11, H12, H13, H16 and H17 and variants thereof and one or more influenza A virus group 2 subtype selected from H3, H4, H7, H1, 0, H14 and H15 and variants thereof.

The disclosure relates to compositions, assays, methods and kits comprising one or more amino acid sequences of a filovirus protein, or a fragment thereof, which find use in the detection of a filovirus infection and/or the presence of antibodies specific for a filovirus in a biological sample.

The present disclosure relates to polypeptides that specifically bind to Dengue virus non¬structural protein 1, including antibodies and fragments thereof. The antibody or antigen-binding fragment thereof may specifically bind Dengue virus (DENV) serotype 4 and include: a heavy chain variable region that comprises at least one CDR amino acid sequence selected from the group consisting of: SGYNWH, YIH YS GGTN YNPS LKS, RTGTVPFAY, SYVMH, YLNPYNDDTKYNEKFKG, and GPPYALDY. The present disclosure further relates to methods of producing the polypeptides of the present disclosure, methods of diagnosing DENV, and methods of treating a DENV infection.

The invention proposes a testing device and method for detecting infection with or immunity to SARS-Cov-2 of a subject, the method comprising the following steps: (i) contacting a urine sample from the subject with an application area of a testing device comprising a urine sorption material defining a sequence of said application area, a conjugate area and a testing area, the areas being in direct or indirect capillary flow communication with each other, (ii) allowing the urine sample to flow by capillarity from said application area to said conjugate area, said conjugate area comprising a testing conjugate movably held therein, wherein said testing conjugate comprises or consists of a polypeptide having an amino acid sequence that shares sequence identity of at least 90%, preferably at least 95%, with a SARS-CoV-2 protein or fragment thereof, coupled to a first colored marker, (iii) allowing the urine sample to continue to flow by capillarity to the testing area, said testing area comprising a testing sub-area with immobilized anti-human IgA antibodies, and (iv) determining infection with or immunity SARS-CoV-2 of the subject by visually inspecting the testing sub-area of the testing area for a color build-up, wherein the presence of a color build-up is indicative of said infection with or immunity to SARS-CoV-2.

The present invention is directed to a method, i.e. an immunoassay, for determining the presence and/or the amount of anti-zika Anti-ZIKV #1 virus antibodies, i.e. zika virus-specific antibodies in a sample. Therefore, the present invention is directed to a microsphere complex comprising a microsphere coupled to a zika virus like particle, as well as to a kit comprising said microsphere complex and an amount of reporter antibody that binds to the zika virus like particle. The present invention further relates to a method for determining an antibody correlate of protection against zika virus infection for a zika virus vaccine. Moreover, the present invention is directed to a method for diagnosing the protection of a human or non-human subject against a zika virus infection.

Novel antibody pairs for use in an Influenza A diagnostic test.

The present disclosure provides polypeptides, and nucleic acids encoding the polypeptides, that include severe acute respiratory syndrome Co-V-2 (SARS-CoV-2) spike polypeptide receptor-binding domain (RBD) polypeptides or variants thereof, which are capable of multimerization and thus presenting multiple copies of the RBD to enhance the immune response generated when the polypeptide is administered to a subject. The disclosure also provides multimers, scaffolds, compositions, pharmaceutical compositions, and vaccines that include the polypeptides and/or nucleic acids that encode such polypeptides.

In alternative embodiments, provided are multiplexed systems, compositions, including products of manufacture such as arrays, microarrays and biochips, and kits, and methods, for detecting presence of a coronavirus in a sample, or to detect a coronavirus, e.g., COVID-19, infection. In alternative embodiments, provided are methods for detecting the presence of a coronavirus infection in an individual. In alternative embodiments, provided are vaccines and methods for using them to prevent, mitigate or lessen to effects of, or treat a coronavirus infection in an individual.